Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on LinkedIn:
“No age barrier for immunotherapy in renal cell carcinoma — but smarter prognostic tools can help guide decisions.
Background:
Renal cell carcinoma (RCC) incidence increases with age, yet older patients remain underrepresented in clinical trials.
Our study: Real-world multicenter analysis of 889 patients with metastatic RCC treated with nivolumab (alone or with ipilimumab), including 336 aged ≥70 years.
Key findings:
Comparable outcomes between older and younger patients
Median OS: 25.1 vs 23.5 months (HR 1.02, p=0.82)
Age should not be a barrier to immunotherapy in fit older adults with mRCC
Prognostic refinement:
The Meet-URO score — which integrates NLR and bone metastases with the IMDC model —
- Offers superior prognostic accuracy (c-index 0.66 vs 0.63)
- Identifies five risk groups with clearly distinct outcomes
- Median OS ranges from 50 to 3.7 months across groups
Clinical relevance:
The Meet-URO score helps:
- Improve patient stratification and counseling
- Support shared decision-making
- Balance hope with realism in treatment discussions
Take-home message:
it older adults can benefit from immunotherapy as much as younger patients — and the Meet-URO score helps us tailor conversations and expectations with greater precision.”
Title: Effectiveness of Nivolumab-Based Immunotherapy and Prognostic Stratification by the Meet-URO Score in Real-World Older Patients with Metastatic RCC
Authors: Veronica Murianni, Marina Campione, Malvina Cremante, Umberto Basso, Lucia Fratino, Sebastiano Buti, Sergio Bracarda, Marco Maruzzo, Ugo De Giorgi, Giampaolo Tortora, Silvia Chiellino, Lorenzo Antonuzzo, Luca Galli, Paolo Andrea Zucali, Mimma Rizzo, Alessio Signori, Diana Giannarelli, Giuseppe Procopio, Pasquale Rescigno, Giuseppe Fornarini, Sara Elena Rebuzzi, Giuseppe Luigi Banna
Read the Full Article.
More from Giuseppe Banna on OncoDaily.
